Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has driven 31% Fanapt sales growth, but resulted in higher cash burn and quarterly losses. Key regulatory catalysts loom with PDUFA dates for Bysanti and tradipitant, and tradipitant's GLP-1 adjunct potential offers significant upside.
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. ( VNDA ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Kevin Moran - Senior VP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, and thank you for standing by.
Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement
Vanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar I/schizophrenia (Feb 2026) and phase 3 data for MDD, plus tradipitant's motion sickness PDUFA (Dec 2025). Vanda's pipeline features a selective JAK2 inhibitor for polycythemia vera, recently granted Orphan Drug Designation, targeting a growing $2B market by 2032.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Kevin Patrick Moran - Senior VP, CFO & Treasurer Mihael H. Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C.
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.08 per share a year ago.
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 results being announced in February.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
